Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$803K Sell
2,218
-26
-1% -$8.9K 0.23% 92
2026
Q1
$790K Buy
2,244
+239
+12% +$85.2K 0.27% 78
2025
Q4
$656K Sell
2,005
-103
-5% -$32.7K 0.24% 88
2025
Q3
$595K Sell
2,108
-252
-11% -$73.1K 0.24% 100
2025
Q2
$659K Buy
2,360
+153
+7% +$43.3K 0.3% 76
2025
Q1
$688K Buy
2,207
+145
+7% +$42.8K 0.37% 60
2024
Q4
$537K Sell
2,062
-176
-8% -$52.2K 0.27% 93
2024
Q3
$721K Sell
2,238
-586
-21% -$192K 0.37% 63
2024
Q2
$882K Buy
2,824
+332
+13% +$97.5K 0.44% 49
2024
Q1
$709K Sell
2,492
-1,522
-38% -$445K 0.43% 62
2023
Q4
$1.16M Buy
+4,014
New +$1.09M 0.54% 36

Other funds holding AMGN

Everpar Advisors's AMGN Position: Q2 2026 in Review

Everpar Advisors reduced its Amgen (AMGN) stake by 1.2% in Q2 2026, selling an estimated $8.9K and leaving 2,218 shares worth $803K. The position accounts for 0.23% of the portfolio, ranked #92.

Everpar Advisors first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.16M in Q4 2023. 577 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Everpar Advisors held 2,218 shares of Amgen worth $803K as of Q2 2026.
  • Everpar Advisors sold 26 Amgen shares in Q2 2026, an estimated $8.9K.
  • Amgen made up 0.23% of Everpar Advisors's portfolio in Q2 2026, its #92 holding.
  • Everpar Advisors first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • Everpar Advisors's Amgen position peaked at $1.16M in Q4 2023.
  • 577 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Everpar Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.